ebomi
Colour theme
Sign in
Insider · CIK 0001559807

Sonsini Peter W.

CIK 0001559807 Name as filed on the most recent filing

Filed as Sonsini Peter W. (78)

129 transaction lines · from 78 filings · filed 2014-08-06 to 2022-06-23 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-25 05:24 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

80 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-25 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2021-04-13 P, Open-market purchase Reneo Pharmaceuticals, Inc.RPHM 9,999,990, acquired Open Form 4 filing 0001209191-21-026862
2021-03-16 P, Open-market purchase Marker Therapeutics, Inc.MRKR 9,999,999, acquired Open Form 4 filing 0001209191-21-021817
2020-12-04 P, Open-market purchase Regulus Therapeutics Inc.RGLS 2,735,930, acquired Open Form 4 filing 0001209191-20-061975
2020-10-20 P, Open-market purchase Eargo, Inc.EAR 5,599,998, acquired Open Form 4 filing 0001209191-20-055622
2020-09-18 P, Open-market purchase Metacrine, Inc.MTCR 9,999,990, acquired Open Form 4 filing 0001209191-20-051534
2020-07-28 P, Open-market purchase Inozyme Pharma, Inc.INZY 4,000,000, acquired Open Form 4 filing 0001209191-20-043886
2020-07-24 P, Open-market purchase Genocea Biosciences, Inc.GNCA 7,090,335, acquired Open Form 4 filing 0001209191-20-043871
2020-07-14 P, Open-market purchase Nkarta, Inc.NKTK 11,999,988, acquired Open Form 4 filing 0001209191-20-042655
2020-06-30 P, Open-market purchase Akouos, Inc.AKUS 9,999,995, acquired Open Form 4 filing 0001209191-20-039876
2020-06-19 P, Open-market purchase Aveo Pharmaceuticals, Inc.AVEO 7,499,998, acquired Open Form 4 filing 0001209191-20-038246
2020-05-20 S, Open-market sale Surface Oncology, Inc.SURF 1,535,562, disposed Open Form 4 filing 0001209191-20-031786
2020-04-03 S, Open-market sale Trevi Therapeutics, Inc.TRVI 1,500, disposed Open Form 4 filing 0001209191-20-024289
2020-03-16 P, Open-market purchase Imara Inc.IMRA 7,600,000, acquired Open Form 4 filing 0001209191-20-019337
2020-03-06 S, Open-market sale Champions Oncology, Inc.CSBR 4,950,003, disposed Open Form 4 filing 0001209191-20-017699
2020-02-10 P, Open-market purchase Casper Sleep Inc.CSPR 15,000,000, acquired Open Form 4 filing 0001209191-20-008757
2020-01-24 P, Open-market purchase Adaptimmune Therapeutics PLCADAP 5,000,250, acquired Open Form 4 filing 0001209191-20-005173
2019-11-12 P, Open-market purchase Galera Therapeutics, Inc.GRTX 4,999,992, acquired Open Form 4 filing 0001209191-19-056068
2019-11-04 P, Open-market purchase Oyster Point Pharma, Inc.OYST 14,960,000, acquired Open Form 4 filing 0001209191-19-055017
2019-08-28 S, Open-market sale Mersana Therapeutics, Inc.MRSN 3,524, disposed Open Form 4 filing 0001209191-20-024272
2019-07-22 P, Open-market purchase Mirum Pharmaceuticals, Inc.MIRM 6,750,000, acquired Open Form 4 filing 0001209191-19-043062
2019-06-24 P, Open-market purchase Genocea Biosciences, Inc.GNCA 9,999,997, acquired Open Form 4 filing 0001209191-19-038967
2019-05-09 P, Open-market purchase Trevi Therapeutics, Inc.TRVI 2 lines 25,000,000, acquired Open Form 4 filing 0001209191-19-029404
2019-05-07 P, Open-market purchase Regulus Therapeutics Inc.RGLS 1,227,640, acquired Open Form 4 filing 0001209191-19-028606
2019-04-08 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 4,956,523, acquired Open Form 4 filing 0001209191-19-024005
2019-03-05 P, Open-market purchase Mersana Therapeutics, Inc.MRSN 15,000,000, acquired Open Form 4 filing 0001209191-19-017378
2019-02-14 P, Open-market purchase Genocea Biosciences, Inc.GNCA 4,688,619, acquired Open Form 4 filing 0001209191-19-011173
2018-12-21 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 448,380, acquired Open Form 4 filing 0001209191-18-064032
2018-12-20 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 326,060, acquired Open Form 4 filing 0001209191-18-064032
2018-12-11 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 121,084, acquired Open Form 4 filing 0001209191-18-062258
2018-12-10 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 51,576, acquired Open Form 4 filing 0001209191-18-061842
2018-12-07 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 232,362, acquired Open Form 4 filing 0001209191-18-061842
2018-12-06 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 54,414, acquired Open Form 4 filing 0001209191-18-061842
2018-11-30 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 142,067, acquired Open Form 4 filing 0001209191-18-060423
2018-11-28 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 48,824, acquired Open Form 4 filing 0001209191-18-060423
2018-11-20 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 336,107, acquired Open Form 4 filing 0001209191-18-059732
2018-11-19 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 956,658, acquired Open Form 4 filing 0001209191-18-059353
2018-11-16 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 649,355, acquired Open Form 4 filing 0001209191-18-059353
2018-11-15 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 631,958, acquired Open Form 4 filing 0001209191-18-059353
2018-09-07 P, Open-market purchase Adaptimmune Therapeutics PLCADAP 2 lines 25,000,500, acquired Open Form 4 filing 0001209191-18-050292
2018-08-21 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 1,499,998, acquired Open Form 4 filing 0001209191-18-047971
2018-07-19 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 101,165, acquired Open Form 4 filing 0001209191-18-043487
2018-07-18 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 390,580, acquired Open Form 4 filing 0001209191-18-043487
2018-06-28 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 392,692, acquired Open Form 4 filing 0001209191-18-039968
2018-06-27 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 11,384, acquired Open Form 4 filing 0001209191-18-039968
2018-05-30 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 591, acquired Open Form 4 filing 0001209191-18-034192
2018-05-21 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 69,059, acquired Open Form 4 filing 0001209191-18-031989
2018-05-18 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 42,928, acquired Open Form 4 filing 0001209191-18-031989
2018-05-17 P, Open-market purchase Aveo Pharmaceuticals IncAVEO 391,436, acquired Open Form 4 filing 0001209191-18-031989

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Search the catalog
Codes on this page
P, Open-market purchase
Open-market purchase
S, Open-market sale
Open-market sale
Relationships on this page
%, Ten percent owner
Ten percent owner

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 71
  • Open-market sale 9
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Sonsini Peter W., insider transactions. Retrieved 2026-08-25 from https://ebomi.com/insider/0001559807

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.